NGF (next generation flow) para detectar EMR en MM y células plasmáticas tumorales circulantes en Gammapatias monoclonales

Ponente: Luzalba Sanoja-Flores

Centro de Investigación del Cáncer (CIC-IBMCC), laboratorio 11.

Host: -

Fecha: 28/04/2016

Hora: 12:30

Salón de Actos del CIC

Flow cytometry has become one of the preferred methods to monitor minimal residual disease (MRD) and evaluate the depth of complete remission (CR) in the bone marrow (BM) of multiple myeloma (MM) patients after therapy. However, flow-MRD has lower sensitivity vs molecular methods and lacks standardization. We have designed and validated a next generation flow (NGF) approach for high-sensitive and standardized detection of MRD in MM based in innovative tools and procedures developed by the EuroFlow group and International Myeloma Foundation (IMF), which involve sample preparation, optimized antibody panel combination and automatic identification of plasma cell (PC) against reference databases of normal and patient BM. Additionally, detection of circulating clonal PC (cPC) in peripheral blood (PB) in newly plasma cell disease (PCD) diagnosed patients have been associated with poor prognosis and increased risk of transformation to more aggressive forms of the disease. We applied the NGF-MM MRD approach for high sensitive detection of cPC in the PB and to evaluate its utility as a reflection of BM cPC involvement, of potential utility as a diagnostic, classification and risk signification tool in newly diagnosed MM and monoclonal gammopathy of undetermined significance (MGUS) patients.